Using mitochondrial therapy alongside standard heart failure treatments
Mitochondrial therapy in conjunction with guideline directed medical therapy in cardiomyopathy
This study is looking at how adding a special treatment that helps heart cells to a standard heart failure medication might improve health for people with heart failure, and you could have the chance to join in and see if this new approach works better for you.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Stanford University NIH-funded |
| Lab location | 1 site (Stanford, United States) |
| Project ID | NIH-10997199 on NIH RePORTER |
What this research studies
This research investigates the potential benefits of combining mitochondrial therapy with current guideline-directed medical therapy (GDMT) for patients with heart failure. It focuses on the use of mitochondria-rich extracellular vesicles (M-EVs) to enhance the function and viability of heart cells that have been damaged. By employing an innovative model of heart cell injury, the study aims to understand how these therapies can work together to improve patient outcomes. Patients may have the opportunity to participate in trials assessing the effectiveness of this combined approach.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with heart failure or cardiomyopathy who are currently receiving or are eligible for guideline-directed medical therapy.
Not a fit: Patients with heart failure who are not candidates for standard medical therapies or those with advanced heart failure requiring surgical interventions may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatments for heart failure, potentially enhancing heart function and patient quality of life.
How similar studies have performed: Previous research has shown promising results with mitochondrial therapies in other contexts, suggesting potential for success in this novel application.
Where this research is happening
Stanford, United States
- Stanford University — Stanford, United States (Active)
Researchers
- Principal investigator: Li, Jiwen — Stanford University
- Study coordinator: Li, Jiwen
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.